Annual report
4885.TEDINET S100P2VN
Period2021-06-01 → 2022-05-31
Filed2022-08-26
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 96
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥5.7bn | 2021-06-01 → 2022-05-31 | Standalone | Net sales |
| Revenue | ¥4.9bn | 2020-06-01 → 2021-05-31 | Standalone | Net sales |
| Revenue | ¥5.3bn | 2019-06-01 → 2020-05-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥5.4bn | 2018-06-01 → 2019-05-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥5.4bn | 2018-06-01 → 2019-05-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥4.5bn | 2017-06-01 → 2018-05-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥437m | 2021-06-01 → 2022-05-31 | Standalone | Operating income |
| Operating income | ¥369m | 2020-06-01 → 2021-05-31 | Standalone | Operating income |
| Ordinary income | ¥423m | 2021-06-01 → 2022-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥339m | 2020-06-01 → 2021-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥272m | 2019-06-01 → 2020-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥278m | 2019-06-01 → 2020-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥91m | 2018-06-01 → 2019-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥108m | 2018-06-01 → 2019-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥20m | 2017-06-01 → 2018-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥426m | 2021-06-01 → 2022-05-31 | Standalone | Income before income taxes |
| Profit before tax | ¥200m | 2020-06-01 → 2021-05-31 | Standalone | Income before income taxes |
| Net income (owners) | ¥32m | 2019-06-01 → 2020-05-31d | Standalone | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥29m | 2018-06-01 → 2019-05-31d | Standalone | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥456m | 2021-06-01 → 2022-05-31 | Standalone | Profit loss |
| Net income | ¥181m | 2020-06-01 → 2021-05-31 | Standalone | Profit loss |
| Net income | ¥34m | 2019-06-01 → 2020-05-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥112m | 2018-06-01 → 2019-05-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥88m | 2017-06-01 → 2018-05-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥4.8bn | at 2022-05-31 | Standalone | Assets |
| Total assets | ¥4.6bn | at 2021-05-31 | Standalone | Assets |
| Total assets | ¥4.8bn | at 2020-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.6bn | at 2019-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.6bn | at 2019-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.7bn | at 2018-05-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥3.1bn | at 2022-05-31 | Standalone | Liabilities |
| Total liabilities | ¥3.3bn | at 2021-05-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.7bn | at 2022-05-31 | Standalone | Net assets |
| Net assets / equity | ¥1.3bn | at 2021-05-31 | Standalone | Net assets |
| Net assets / equity | ¥252m | at 2020-05-31d | Standalone | Net assets |
| Net assets / equity | ¥182m | at 2019-05-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥179m | at 2019-05-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥71m | at 2018-05-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥865m | at 2022-05-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.0bn | at 2021-05-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥865m | at 2022-05-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.0bn | at 2021-05-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥881m | at 2020-05-31d | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥614m | at 2019-05-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥525m | 2021-06-01 → 2022-05-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | ¥488m | 2020-06-01 → 2021-05-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | ¥89m | 2019-06-01 → 2020-05-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥342m | 2018-06-01 → 2019-05-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥176m | 2021-06-01 → 2022-05-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥58m | 2020-06-01 → 2021-05-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | ¥137m | 2019-06-01 → 2020-05-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥311m | 2018-06-01 → 2019-05-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥484m | 2021-06-01 → 2022-05-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | −¥311m | 2020-06-01 → 2021-05-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥42m | 2019-06-01 → 2020-05-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥23m | 2018-06-01 → 2019-05-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥123.79 | 2021-06-01 → 2022-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥65.24 | 2020-06-01 → 2021-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.75 | 2019-06-01 → 2020-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.16 | 2019-06-01 → 2020-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥14.46 | 2018-06-01 → 2019-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥55.99 | 2018-06-01 → 2019-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-219.58 | 2017-06-01 → 2018-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥112.56 | 2021-06-01 → 2022-05-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥56.97 | 2020-06-01 → 2021-05-31 | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥19 | 2021-06-01 → 2022-05-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2020-06-01 → 2021-05-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥3 | 2019-06-01 → 2020-05-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥3 | 2018-06-01 → 2019-05-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥3 | 2017-06-01 → 2018-05-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥450.37 | at 2022-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥363.93 | at 2021-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥101.92 | at 2020-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥91.2 | at 2019-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥89.32 | at 2019-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥178.52 | at 2018-05-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 35.0% | at 2022-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.9% | at 2021-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 5.3% | at 2020-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 3.9% | at 2019-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 1.5% | at 2018-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 30.3% | 2021-06-01 → 2022-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 22.8% | 2020-06-01 → 2021-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.0% | 2019-06-01 → 2020-05-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.9% | 2018-06-01 → 2019-05-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 89.6% | 2018-06-01 → 2019-05-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 4,095,500 | at 2022-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,095,500 | at 2021-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 775,000 | at 2020-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,010,000 | at 2019-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,010,000 | at 2018-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 197 | at 2022-05-31 | Standalone | Number of employees |
| Employees | 195 | at 2021-05-31 | Standalone | Number of employees |
| Employees | 196 | at 2020-05-31d | Standalone | Number of employees |
| Employees | 199 | at 2019-05-31d | Standalone | Number of employees |
| Employees | 199 | at 2018-05-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 53
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment assets | at 2022-05-31 | ¥1.3bn |
| Chemical Products Businessreportable segment | capex | 2021-06-01 → 2022-05-31 | ¥39m |
| Chemical Products Businessreportable segment | depreciation | 2021-06-01 → 2022-05-31 | ¥55m |
| Chemical Products Businessreportable segment | employees | at 2022-05-31 | 50 pure |
| Chemical Products Businessreportable segment | revenue | 2021-06-01 → 2022-05-31 | ¥1.9bn |
| Chemical Products Businessreportable segment | revenue external | 2021-06-01 → 2022-05-31 | ¥1.9bn |
| Chemical Products Businessreportable segment | segment assets | at 2022-05-31 | ¥1.2bn |
| Chemical Products Businessreportable segment | segment profit | 2021-06-01 → 2022-05-31 | −¥16m |
| Healthy Food Businessreportable segment | capex | 2021-06-01 → 2022-05-31 | ¥116m |
| Healthy Food Businessreportable segment | depreciation | 2021-06-01 → 2022-05-31 | ¥11m |
| Healthy Food Businessreportable segment | employees | at 2022-05-31 | 27 pure |
| Healthy Food Businessreportable segment | revenue | 2021-06-01 → 2022-05-31 | ¥824m |
| Healthy Food Businessreportable segment | revenue external | 2021-06-01 → 2022-05-31 | ¥824m |
| Healthy Food Businessreportable segment | segment assets | at 2022-05-31 | ¥399m |
| Healthy Food Businessreportable segment | segment profit | 2021-06-01 → 2022-05-31 | ¥1m |
| Pharmaceutical Businessreportable segment | capex | 2021-06-01 → 2022-05-31 | ¥58m |
| Pharmaceutical Businessreportable segment | depreciation | 2021-06-01 → 2022-05-31 | ¥36m |
| Pharmaceutical Businessreportable segment | employees | at 2022-05-31 | 44 pure |
| Pharmaceutical Businessreportable segment | revenue | 2021-06-01 → 2022-05-31 | ¥2.9bn |
| Pharmaceutical Businessreportable segment | revenue external | 2021-06-01 → 2022-05-31 | ¥2.9bn |
| Pharmaceutical Businessreportable segment | segment assets | at 2022-05-31 | ¥2.0bn |
| Pharmaceutical Businessreportable segment | segment profit | 2021-06-01 → 2022-05-31 | ¥452m |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-06-01 → 2022-05-31 | ¥213m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-06-01 → 2022-05-31 | ¥101m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-06-01 → 2022-05-31 | ¥5.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-06-01 → 2022-05-31 | ¥5.7bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-05-31 | ¥3.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-06-01 → 2022-05-31 | ¥437m |
| Reconciling Itemsreconciling | segment assets | at 2021-05-31 | ¥1.3bn |
| Chemical Products Businessreportable segment | capex | 2020-06-01 → 2021-05-31 | ¥15m |
| Chemical Products Businessreportable segment | depreciation | 2020-06-01 → 2021-05-31 | ¥67m |
| Chemical Products Businessreportable segment | revenue | 2020-06-01 → 2021-05-31 | ¥1.7bn |
| Chemical Products Businessreportable segment | revenue external | 2020-06-01 → 2021-05-31 | ¥1.7bn |
| Chemical Products Businessreportable segment | segment assets | at 2021-05-31 | ¥1.2bn |
| Chemical Products Businessreportable segment | segment profit | 2020-06-01 → 2021-05-31 | −¥61m |
| Healthy Food Businessreportable segment | capex | 2020-06-01 → 2021-05-31 | ¥4m |
| Healthy Food Businessreportable segment | depreciation | 2020-06-01 → 2021-05-31 | ¥22m |
| Healthy Food Businessreportable segment | revenue | 2020-06-01 → 2021-05-31 | ¥800m |
| Healthy Food Businessreportable segment | revenue external | 2020-06-01 → 2021-05-31 | ¥800m |
| Healthy Food Businessreportable segment | segment assets | at 2021-05-31 | ¥376m |
| Healthy Food Businessreportable segment | segment profit | 2020-06-01 → 2021-05-31 | −¥44m |
| Pharmaceutical Businessreportable segment | capex | 2020-06-01 → 2021-05-31 | ¥16m |
| Pharmaceutical Businessreportable segment | depreciation | 2020-06-01 → 2021-05-31 | ¥35m |
| Pharmaceutical Businessreportable segment | revenue | 2020-06-01 → 2021-05-31 | ¥2.5bn |
| Pharmaceutical Businessreportable segment | revenue external | 2020-06-01 → 2021-05-31 | ¥2.5bn |
| Pharmaceutical Businessreportable segment | segment assets | at 2021-05-31 | ¥1.7bn |
| Pharmaceutical Businessreportable segment | segment profit | 2020-06-01 → 2021-05-31 | ¥475m |
| Total Of Reportable Segments And Otherssegment total | capex | 2020-06-01 → 2021-05-31 | ¥35m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2020-06-01 → 2021-05-31 | ¥124m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2020-06-01 → 2021-05-31 | ¥4.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2020-06-01 → 2021-05-31 | ¥4.9bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2021-05-31 | ¥3.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2020-06-01 → 2021-05-31 | ¥369m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,194
| Item | Context | Value | Unit |
|---|---|---|---|
| Vehicles net | CurrentYearInstant_NonConsolidatedMember | 688000 | JPY |
| Tools furniture and fixtures | Prior1YearInstant_NonConsolidatedMember | 271565000 | JPY |
| Tools furniture and fixtures | CurrentYearInstant_NonConsolidatedMember | 273606000 | JPY |
| Accumulated depreciation tools furniture and fixtures | Prior1YearInstant_NonConsolidatedMember | -248833000 | JPY |
| Accumulated depreciation tools furniture and fixtures | CurrentYearInstant_NonConsolidatedMember | -253649000 | JPY |
| Tools furniture and fixtures net | Prior1YearInstant_NonConsolidatedMember | 22732000 | JPY |
| Tools furniture and fixtures net | CurrentYearInstant_NonConsolidatedMember | 19956000 | JPY |
| Collective depreciable asset ppe | Prior1YearInstant_NonConsolidatedMember | 1653000 | JPY |
| Collective depreciable asset ppe | CurrentYearInstant_NonConsolidatedMember | 2424000 | JPY |
| Land | Prior1YearInstant_NonConsolidatedMember | 260431000 | JPY |
| Land | CurrentYearInstant_NonConsolidatedMember | 260431000 | JPY |
| Lease assets ppe | Prior1YearInstant_NonConsolidatedMember | 7530000 | JPY |
| Lease assets ppe | CurrentYearInstant_NonConsolidatedMember | 7530000 | JPY |
| Accumulated depreciation lease assets ppe | Prior1YearInstant_NonConsolidatedMember | -4051000 | JPY |
| Accumulated depreciation lease assets ppe | CurrentYearInstant_NonConsolidatedMember | -5371000 | JPY |
| Lease assets net ppe | Prior1YearInstant_NonConsolidatedMember | 3479000 | JPY |
| Lease assets net ppe | CurrentYearInstant_NonConsolidatedMember | 2159000 | JPY |
| Construction in progress | Prior1YearInstant_NonConsolidatedMember | 5220000 | JPY |
| Construction in progress | CurrentYearInstant_NonConsolidatedMember | 95054000 | JPY |
| Property plant and equipment | Prior1YearInstant_NonConsolidatedMember | 834118000 | JPY |
| Property plant and equipment | CurrentYearInstant_NonConsolidatedMember | 908054000 | JPY |
| Software | Prior1YearInstant_NonConsolidatedMember | 12707000 | JPY |
| Software | CurrentYearInstant_NonConsolidatedMember | 18129000 | JPY |
| Software in progress | Prior1YearInstant_NonConsolidatedMember | - | JPY |
| Software in progress | CurrentYearInstant_NonConsolidatedMember | 21902000 | JPY |
| Intangible assets | Prior1YearInstant_NonConsolidatedMember | 12707000 | JPY |
| Intangible assets | CurrentYearInstant_NonConsolidatedMember | 40031000 | JPY |
| Investment securities | Prior1YearInstant_NonConsolidatedMember | 48829000 | JPY |
| Investment securities | CurrentYearInstant_NonConsolidatedMember | 44111000 | JPY |
| Investments in capital | Prior1YearInstant_NonConsolidatedMember | 30000 | JPY |
| Investments in capital | CurrentYearInstant_NonConsolidatedMember | 30000 | JPY |
| Long term prepaid expenses | Prior1YearInstant_NonConsolidatedMember | 7148000 | JPY |
| Long term prepaid expenses | CurrentYearInstant_NonConsolidatedMember | 20467000 | JPY |
| Deferred tax assets | Prior1YearInstant_NonConsolidatedMember | 161646000 | JPY |
| Deferred tax assets | CurrentYearInstant_NonConsolidatedMember | 231436000 | JPY |
| Other ioa | Prior1YearInstant_NonConsolidatedMember | 53329000 | JPY |
| Other ioa | CurrentYearInstant_NonConsolidatedMember | 59259000 | JPY |
| Investments and other assets | Prior1YearInstant_NonConsolidatedMember | 270984000 | JPY |
| Investments and other assets | CurrentYearInstant_NonConsolidatedMember | 355304000 | JPY |
| Noncurrent assets | Prior1YearInstant_NonConsolidatedMember | 1117810000 | JPY |
| Noncurrent assets | CurrentYearInstant_NonConsolidatedMember | 1303391000 | JPY |
| Assets | Prior1YearInstant_NonConsolidatedMember | 4612324000 | JPY |
| Assets | CurrentYearInstant_NonConsolidatedMember | 4798071000 | JPY |
| Notes payable trade | Prior1YearInstant_NonConsolidatedMember | 35746000 | JPY |
| Notes payable trade | CurrentYearInstant_NonConsolidatedMember | 41818000 | JPY |
| Electronically recorded obligations operating cl | Prior1YearInstant_NonConsolidatedMember | 160600000 | JPY |
| Electronically recorded obligations operating cl | CurrentYearInstant_NonConsolidatedMember | 131492000 | JPY |
| Accounts payable trade | Prior1YearInstant_NonConsolidatedMember | 370584000 | JPY |
| Accounts payable trade | CurrentYearInstant_NonConsolidatedMember | 664230000 | JPY |
| Short term loans payable | Prior1YearInstant_NonConsolidatedMember | 850000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 13 of 13 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |